Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): A prospective evaluation of 150 colorectal cancer patients

Annals of Oncology

Volumn 23, Issue 12, 2012, Pages 3116-3122

  Argyriou, A A ^a,b   Velasco, R ^g   Briani, C ^c   Cavaletti, G ^d   Bruna, J ^g   Alberti, P ^d   Cacciavillani, M ^e   Lonardi, S ^f   Santos, C ^g   Cortinovis, D ^h   Cazzaniga, M ^h   Kalofonos, H P ^g  

^a UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e CEMES   (Italy)

^f VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h SAN GERARDO HOSPITAL   (Italy)

Author keywords

Folfox 4; Incidence; Oxaliplatin; Peripheral neurotoxicity; Xelox

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; COLD INDUCED PERIORAL DYSESTHESIA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARYNGOLARYNGEAL DYSESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84869781635     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds208     Document Type: Article

References (37)

1. Jemal A, Siegel R, Xu J et al. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (5): 277-300.
2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M et al. for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350(23): 2343-2351.
3. Chau I, Cunningham D. Adjuvant therapy in colon cancer-what, when and how? Ann Oncol 2006; 17(9): 1347-1359.
4. Golfinopoulos V, Salanti G, Pavlidis N et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007; 8(10): 898-911.
5. Rothenberg ML, Cox JV, Butts C et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 2008; 19(10): 1720-2726.
6. Argyriou AA, Polychronopoulos P, Iconomou G et al. A review on oxaliplatininduced peripheral nerve damage. Cancer Treat Rev 2008; 34(4): 368-377.
7. Argyriou AA, Zolota V, Kyriakopoulou O et al. Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents. J BUON 2010; 15(3): 435-446.
8. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004; 5(10): 2159-2170.
9. Kalofonos HP, Aravantinos G, Kosmidis P et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 2005; 16(6): 869-877.
10. Argyriou AA, Polychronopoulos P, Iconomou G et al. Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer. Acta Oncol 2007; 46: 1131-1137.
11. Land SR, Kopec JA, Cecchini RS et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25(16): 2205-2211.
12. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16): 2938-2947.
13. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22(11): 2084-2091.
14. Storey DJ, Sakala M, McLean CM et al. Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol. 2010; 21(8): 1657-1661.
15. National Cancer Institute: Common Toxicity Criteria version 3.0. (CTCAE v3.0), 2003. Available at: http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/docs/ctcaev3.pdf.
16. Cavaletti G, Jann S, Pace A, Plasmati R, Siciliano G, Briani C, Cocito D, Padua L, Ghiglione E, Manicone M, Giussani G; Italian NETox Group. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006; 11: 135-141.
17. Cavaletti G, Frigeni B, Lanzani F et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-common toxicity scale. J Peripher Nerv Syst 2007; 12: 210-215.
18. Cavaletti G, Frigeni B, Lanzani F et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010; 46(3): 479-494.
19. Antonacopoulou AG, Argyriou AA, Scopa CD et al. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol 2010; 17(7): 963-968.
20. Kimura J. Electrodiagnosis in diseases of nerve and muscle, principles and practice, 3rd edition. New York, USA: Oxford University press 2001: 91-166.
21. Pasetto LM, D'Andrea MR, Rossi E et al. Oxaliplatin-related neurotoxicity: How and why? Crit Rev Oncol Hematol 2006; 59: 159-168.
22. Argyriou AA, Bruna J, Marmiroli P et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012; 82(1): 51-77.
23. Sittl R, Lampert A, Huth T et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype NaV1.6-resurgent and persistent current. Proc Natl Acad Sci USA 2012; 109(17): 6704-6709.
24. Grolleau F, Gamelin L, Boisdron-Celle M et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85(5): 2293-2297.
25. Gamelin L, Capitain O, Morel A et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 2007; 13(21): 6359-6368.
26. Cavaletti G, Tredici G, Petruccioli MG et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001; 37(18): 2457-2463.
27. Baek KK, Lee J, Park SH et al. Oxaliplatin-induced chronic peripheral neurotoxicity: a prospective analysis in patients with colorectal cancer. Cancer Res Treat 2010; 42(4): 185-190.
28. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12): 2013-2019.
29. Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26(12): 2006-2012.
30. Allegra CJ, Yothers G, O'Connell MJ et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27(20): 3385-3390.
31. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. J Clin Oncol 2007; 25(1): 102-109.
32. Saif MW, Wilson RH, Harold N et al. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 2001; 12 (6): 525-531.
33. Saif MW, Wood TE, McGee PJ et al. Peripheral neuropathy associated with capecitabine. Anticancer Drugs 2004; 15(8): 767-771.
34. Petrioli R, Paolelli L, Marsili S et al. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006; 70(5): 345-350.
35. Maindrault-Goebel F, Tournigand C, André T et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004; 15(8): 1210-1214.
36. Kemeny N, Garay CA, Gurtler J et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004; 22(23): 4753-4761.
37. Maindrault-Goebel F, Louvet C, Andre T et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR Eur J Cancer 1999; 35(9): 1338-1342.